Raymond James Financial
EPRX

Raymond James Financial’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Raymond James Financial’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$354K Buy
53,503
+2,943
+6% +$20.3K ﹤0.01% 4729
2026
Q1 		$366K Sell
50,560
-2,412
-5% -$19.4K ﹤0.01% 4554
2025
Q4 		$400K Buy
52,972
+19,599
+59% +$121K ﹤0.01% 4410
2025
Q3 		$197K Buy
33,373
+21,161
+173% +$115K ﹤0.01% 4626
2025
Q2 		$70.3K Buy
12,212
+1,079
+10% +$4.14K ﹤0.01% 5037
2025
Q1 		$36.5K Sell
11,133
-480
-4% -$1.66K ﹤0.01% 4667
2024
Q4 		$36.8K Buy
+11,613
New +$34.4K ﹤0.01% 4651

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Raymond James Financial's EPRX Position: Q2 2026 in Review

Raymond James Financial increased its Eupraxia Pharmaceuticals (EPRX) stake by 5.8% in Q2 2026, buying an estimated $20.3K and bringing the position to 53,503 shares worth $354K. The position accounts for ﹤0.01% of the portfolio, ranked #4729.

Raymond James Financial first reported a position in EPRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $400K in Q4 2025. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Raymond James Financial held 53,503 shares of Eupraxia Pharmaceuticals worth $354K as of Q2 2026.
  • Raymond James Financial bought 2,943 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $20.3K.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4729 holding.
  • Raymond James Financial first reported a position in Eupraxia Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Eupraxia Pharmaceuticals position peaked at $400K in Q4 2025.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.